aterosklerozАтеросклерозAteroscleroz2078-256X2949-3633НИИТПМ-филиал ИЦиГ СО РАН10.52727/2078-256X-2022-18-2-157-164ateroskleroz-799Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWSАдипокины/цитокины и нарушения липидного обменаAdipokines/cytokines and disturbances in lipid metabolismhttps://orcid.org/0000-0003-4892-0861СпиридоновА. Н.SpiridonovA. N.

Александр Николаевич Спиридонов, врач-ординатор по специальности «Кардиология»

630089, г. Новосибирск, ул. Бориса Богаткова, 175/1

Aleksandr N. Spiridonov, doctor-resident in the specialty «Cardiology»

175/1, Boris Bogatkov str., Novosibirsk, 630089

Spiridonov.al16@yandex.ruhttps://orcid.org/0000-0001-7875-1566ХудяковаА. Д.KhudiakovaA. D.

Алена Дмитриевна Худякова, канд. мед. наук, руководитель лаборатории генетических и средовых детерминант жизненного цикла человека

630089, г. Новосибирск, ул. Бориса Богаткова, 175/1

Alena D. Khudiakova, Ph.D, head of the Laboratory of Genetic and Environmental Determinants of the Human Life Cycle

175/1, Boris Bogatkov str., Novosibirsk, 630089

alene.elene@gmail.comhttps://orcid.org/0000-0002-4936-8362РагиноЮ. И.RaginoYu. I.

Юлия Игоревна Рагино, д-р мед. наук, проф., чл.-корр. РАН, руководитель

630089, г. Новосибирск, ул. Бориса Богаткова, 175/1

Yuliia I. Ragino, DM, professor, corresponding member RAS, head

175/1, Boris Bogatkov str., Novosibirsk, 630089

ragino@mail.ruНаучно-исследовательский институт терапии и профилактической медицины – филиал Федерального государственного бюджетного научного учреждения «Федеральный исследовательский центр Институт цитологии и генетики Сибирского отделения Российской академии наук»Research Institute of Internal and Preventive Medicine – Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences202220072022182157164Copyright © Спиридонов А.Н., Худякова А.Д., Рагино Ю.И., 20222022Спиридонов А.Н., Худякова А.Д., Рагино Ю.И.Spiridonov A.N., Khudiakova A.D., Ragino Y.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://ateroskleroz.elpub.ru/jour/article/view/799

В обзоре представлены результаты исследований в области изучения ассоциации адипокинов, секретируемых висцеральными адипоцитами, и уровня холестерина липопротеинов низкой плотности. В отношении указанной ассоциации проанализированы такие адипокины, как адипонектин, ингибитор активатора плазминогена-1 (PAI-1), резистин, интерлейкин-1 бета (ИЛ-1β), моноцитарно-хемоаттрактантный протеин 1 типа (MCP-1), фактор роста нервов (NGF), висфатин, оментин-1, а также гормон поджелудочной железы инсулин. Представлены результаты исследований, в которых изучены вопросы патогенетической (на животных моделях) и клинической роли данной ассоциации у человека. Использованы сведения по теме из публикаций баз данных PubMed, Google Scholar.

This review presents the results of investigations in the field of studying the association of adipokines secreted by visceral adipocytes and the level of low-density lipoprotein cholesterol. In relation to this association, such adipokines as adiponectin, plasminogen activator inhibitor 1 (PAI-1), resistin, interleukin 1 beta (IL-1β), monocyte-chemoattractant protein type 1 (MCP-1), nerve growth factor (NGF), visfatin, omentin-1, and the pancreatic hormone insulin were analyzed. The results of studies that have studied the pathogenetic (in animal models) and clinical role of this association in humans are presented. Information on the topic from the publications of the PubMed, Google Scholar databases was used. 

адипокиныхолестерин липопротеинов низкой плотностиadipokineslow-density lipoproteins cholesterolЛитературный обзор выполнен в рамках бюджетной темы «Эпидемиологический мониторинг состояния здоровья населения и изучение молекулярно-генетических и молекулярно-биологических механизмов развития распространенных терапевтических заболеваний в Сибири для совершенствования подходов к их диагностике, профилактике и лечению», рег. № 122031700094-5.The literature review was carried out within the framework of the budget topic «Epidemiological monitoring of the health status of the population and the study of molecular genetic and molecular biological mechanisms of the development of common therapeutic diseases in Siberia to improve approaches to their diagnosis, prevention and treatment», reg. No. 122031700094-5.ReferencesCnop M., Havel P.J., Utzschneider K.M., Carr D.B., Sinha M.K., Boyko E.J., Retzlaff B.M., Knopp R.H., Brunzell J.D., Kahn S.E. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia, 2003; 46 (4): 459–469. doi: 10.1007/s00125-003-1074-zCnop M., Havel P.J., Utzschneider K.M., Carr D.B., Sinha M.K., Boyko E.J., Retzlaff B.M., Knopp R.H., Brunzell J.D., Kahn S.E. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia, 2003; 46 (4): 459–469. doi: 10.1007/s00125-003-1074-zEbrahimi R., Shanaki M., Mohassel Azadi S., Bahiraee A., Radmard A.R., Poustchi H., Emamgholipour S. Low level of adiponectin predicts the development of Nonalcoholic fatty liver disease: is it irrespective to visceral adiposity index, visceral adipose tissue thickness and other obesity indices? Arch. Physiol. Biochem., 2022; 128 (1): 24–31. doi: 10.1080/13813455.2019.1661496Ebrahimi R., Shanaki M., Mohassel Azadi S., Bahiraee A., Radmard A.R., Poustchi H., Emamgholipour S. Low level of adiponectin predicts the development of Nonalcoholic fatty liver disease: is it irrespective to visceral adiposity index, visceral adipose tissue thickness and other obesity indices? Arch. Physiol. Biochem., 2022; 128 (1): 24–31. doi: 10.1080/13813455.2019.1661496Kozakova M., Muscelli E., Flyvbjerg A., Frystyk J., Morizzo C., Palombo C., Ferrannini E. Adiponectin and left ventricular structure and function in healthy adults. J. Clin. Endocrinol. Metab., 2008; 93: 2811–2818. doi: 10.1210/jc.2007-2580Kozakova M., Muscelli E., Flyvbjerg A., Frystyk J., Morizzo C., Palombo C., Ferrannini E. Adiponectin and left ventricular structure and function in healthy adults. J. Clin. Endocrinol. Metab., 2008; 93: 2811–2818. doi: 10.1210/jc.2007-2580Yanai H., Yoshida H. Beneficial effects of adiponectin on glucose and lipid metabolism and atherosclerotic progression: Mechanisms and perspectives. Int. J. Mol. Sci., 2019; 20 (5): 1190. doi: 10.3390/ijms20051190Yanai H., Yoshida H. Beneficial effects of adiponectin on glucose and lipid metabolism and atherosclerotic progression: Mechanisms and perspectives. Int. J. Mol. Sci., 2019; 20 (5): 1190. doi: 10.3390/ijms20051190Каратаева О.В. Особенности секреции адипонектина и его связь с некоторыми показателями метаболизма у мужчин трудоспособного возраста при наличии ожирения. Российский меди- цинский журнал, 2017; 23 (6): 312–315. doi: 10.18821/0869-2106-2017-23-6-312-315Karataeva O.V. Features of adiponectin secretion and its relationship with some metabolic parameters in men of working age in the presence of obesity. Rossiiskiy meditsinskiy zhurnal, 2017; 23 (6): 312–315 (In Russ.)Magge S.N., Stettler N., Koren D., Levitt Katz L.E., Gallagher P.R., Mohler E.R., Rader D.J. Adiponectin is associated with favorable lipoprotein profile, independent of BMI and insulin resistance, in adolescents. J. Clin. Endocrinol. Metab., 2011; 96 (5): 1549–1554. doi: 10.1210/jc.2010-2364Magge S.N., Stettler N., Koren D., Levitt Katz L.E., Gallagher P.R., Mohler E.R., Rader D.J. Adiponectin is associated with favorable lipoprotein profile, independent of BMI and insulin resistance, in adolescents. J. Clin. Endocrinol. Metab., 2011; 96 (5): 1549–1554. doi: 10.1210/jc.2010-2364Lautamäki R., Rönnemaa T., Huupponen R., Lehtimäki T., Iozzo P., Airaksinen K.E., Knuuti J., Nuutila P. Low serum adiponectin is associated with high circulating oxidized low-density lipoprotein in patients with type 2 diabetes mellitus and coronary artery disease. Metabolism, 2007; 56 (7): 881–886. doi: 10.1016/j.metabol.2007.01.018Lautamäki R., Rönnemaa T., Huupponen R., Lehtimäki T., Iozzo P., Airaksinen K.E., Knuuti J., Nuutila P. Low serum adiponectin is associated with high circulating oxidized low-density lipoprotein in patients with type 2 diabetes mellitus and coronary artery disease. Metabolism, 2007; 56 (7): 881–886. doi: 10.1016/j.metabol.2007.01.018Liu Y.U., Cheng J., Guo X., Mo J., Gao B., Zhou H., Li Z. The roles of PAI-1 gene polymorphisms in atherosclerotic diseases: A systematic review and metaanalysis involving 149,908 subjects. Gene, 2018; 673: 167–173. doi: 10.1016/j.gene.2018.06.040Liu Y.U., Cheng J., Guo X., Mo J., Gao B., Zhou H., Li Z. The roles of PAI-1 gene polymorphisms in atherosclerotic diseases: A systematic review and metaanalysis involving 149,908 subjects. Gene, 2018; 673: 167–173. doi: 10.1016/j.gene.2018.06.040Jung R.G., Motazedian P., Ramirez F.D., Simard T., di Santo P., Visintini S., Faraz M.A., Labinaz A., Jung Y., Hibbert B. Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis. Thromb. J., 2018; 16: 12. doi: 10.1186/s12959-018-0166-4Jung R.G., Motazedian P., Ramirez F.D., Simard T., di Santo P., Visintini S., Faraz M.A., Labinaz A., Jung Y., Hibbert B. Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis. Thromb. J., 2018; 16: 12. doi: 10.1186/s12959-018-0166-4Sillen M., Declerck P.J. Targeting PAI-1 in cardiovascular disease: structural insights into PAI-1 functionality and inhibition. Front. Cardiovasc. Med., 2020; 7: 364. doi: 10.3389/fcvm.2020.622473Sillen M., Declerck P.J. Targeting PAI-1 in cardiovascular disease: structural insights into PAI-1 functionality and inhibition. Front. Cardiovasc. Med., 2020; 7: 364. doi: 10.3389/fcvm.2020.622473Raiko J.R., Oikonen M., Wendelin-Saarenhovi M., Siitonen N., Kahonen M., Lehtimaki T., Viikari J., Jula A., Loo B.M., Huupponen R., Saarikoski L., Juonala M., Raitakari O.T. Plasminogen activator inhitor-1 associates with cardiovascular risk factors in healthy young adults in the Cardiovascular Risk in Young Finns Study. Atherosclerosis, 2012; 224 (1): 208–212. doi: 10.1016/j.atherosclerosis.2012.06.062Raiko J.R., Oikonen M., Wendelin-Saarenhovi M., Siitonen N., Kahonen M., Lehtimaki T., Viikari J., Jula A., Loo B.M., Huupponen R., Saarikoski L., Juonala M., Raitakari O.T. Plasminogen activator inhitor-1 associates with cardiovascular risk factors in healthy young adults in the Cardiovascular Risk in Young Finns Study. Atherosclerosis, 2012; 224 (1): 208–212. doi: 10.1016/j.atherosclerosis.2012.06.062Somodi S., Seres I., Lorincz H., Harangi M., Fulop P., Paragh G. Plasminogen activator inhibitor-1 level correlates with lipoprotein subfractions in obese nondiabetic subjects. Int. J. Endocrinol., 2018; 2018: 9596054. doi: 10.1155/2018/9596054Somodi S., Seres I., Lorincz H., Harangi M., Fulop P., Paragh G. Plasminogen activator inhibitor-1 level correlates with lipoprotein subfractions in obese nondiabetic subjects. Int. J. Endocrinol., 2018; 2018: 9596054. doi: 10.1155/2018/9596054Levine J.A., Oleaga C., Eren M., Amaral A.P., Shang M., Lux E., Vaughan D.E. Role of PAI-1 in hepatic steatosis and dyslipidemia. Scientific Reports, 2021; 11 (1): 1–13. doi: 10.1038/s41598-020-79948-xLevine J.A., Oleaga C., Eren M., Amaral A.P., Shang M., Lux E., Vaughan D.E. Role of PAI-1 in hepatic steatosis and dyslipidemia. Scientific Reports, 2021; 11 (1): 1–13. doi: 10.1038/s41598-020-79948-xIida K., Tani S., Atsumi W., Yagi T., Kawauchi K., Matsumoto N., Hirayama A. Association of plasminogen activator inhibitor-1 and low-density lipoprotein heterogeneity as a risk factor of atherosclerotic cardiovascular disease with triglyceride metabolic disorder: a pilot cross-sectional study. Coronary Artery Disease, 2017; 28 (7): 577–587. doi: 10.1097/MCA.0000000000000521Iida K., Tani S., Atsumi W., Yagi T., Kawauchi K., Matsumoto N., Hirayama A. Association of plasminogen activator inhibitor-1 and low-density lipoprotein heterogeneity as a risk factor of atherosclerotic cardiovascular disease with triglyceride metabolic disorder: a pilot cross-sectional study. Coronary Artery Disease, 2017; 28 (7): 577–587. doi: 10.1097/MCA.0000000000000521Acquarone E., Monacelli F., Borghi R., Nencioni A., Odetti P. Resistin: A reappraisal. Mechanisms of Ageing and Development, 2019; 178: 46–63. doi: 10.1016/j.mad.2019.01.004Acquarone E., Monacelli F., Borghi R., Nencioni A., Odetti P. Resistin: A reappraisal. Mechanisms of Ageing and Development, 2019; 178: 46–63. doi: 10.1016/j.mad.2019.01.004Tripathi D., Kant S., Pandey S., Ehtesham N.Z. Resistin in metabolism, inflammation, and disease. The FEBS Journal, 2020; 287 (15): 3141–3149. doi: 10.1111/febs.15322Tripathi D., Kant S., Pandey S., Ehtesham N.Z. Resistin in metabolism, inflammation, and disease. The FEBS Journal, 2020; 287 (15): 3141–3149. doi: 10.1111/febs.15322Singh A.K., Tiwari S., Gupta A., Natu S.M., Mittal B., Pant A.B. Аssociation of resistin with metabolic syndrome in Indian subjects. Metab. Syndr. Relat. Disord., 2012; 10 (4): 286–291. doi: 10.1089/met.2011.0128Singh A.K., Tiwari S., Gupta A., Natu S.M., Mittal B., Pant A.B. Аssociation of resistin with metabolic syndrome in Indian subjects. Metab. Syndr. Relat. Disord., 2012; 10 (4): 286–291. doi: 10.1089/met.2011.0128Cabrera de Leon A., Almeida Gonzalez D., Gonzalez Hernandez A., Dominguez Coello S., Marrugat J., Juan Aleman Sanchez J., Brito Diaz B., Marcelino Rodriguez I., Perez Mdel C. Relationships between serum resistin and fat intake, serum lipid concentrations and adiposity in the general population. J. Atheroscler. Thromb., 2014; 21 (5): 454–462. doi: 10.5551/jat.22103Cabrera de Leon A., Almeida Gonzalez D., Gonzalez Hernandez A., Dominguez Coello S., Marrugat J., Juan Aleman Sanchez J., Brito Diaz B., Marcelino Rodriguez I., Perez Mdel C. Relationships between serum resistin and fat intake, serum lipid concentrations and adiposity in the general population. J. Atheroscler. Thromb., 2014; 21 (5): 454–462. doi: 10.5551/jat.22103Melone M., Wilsie L., Palyha O., Strack A., Rashid S. Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/ kexin type 9. J. Am. Coll. Cardiol., 2012; 59 (19): 1697–1705. doi: 10.5551/jat.22103Melone M., Wilsie L., Palyha O., Strack A., Rashid S. Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/ kexin type 9. J. Am. Coll. Cardiol., 2012; 59 (19): 1697–1705. doi: 10.5551/jat.22103Costandi J., Melone M., Zhao A., Rashid S. Human resistin stimulates hepatic overproduction of atherogenic ApoB-containing lipoprotein particles by enhancing ApoB stability and impairing intracellular insulin signaling. Circ. Res., 2011; 108 (6): 727–742. doi: 10.1161/CIRCRESAHA.110.238949Costandi J., Melone M., Zhao A., Rashid S. Human resistin stimulates hepatic overproduction of atherogenic ApoB-containing lipoprotein particles by enhancing ApoB stability and impairing intracellular insulin signaling. Circ. Res., 2011; 108 (6): 727–742. doi: 10.1161/CIRCRESAHA.110.238949Park H.K., Kwak M.K., Kim H.J., Ahima R.S. Linking resistin, inflammation, and cardiometabolic diseases. The Korean Journal of Internal Medicine, 2017; 32 (2): 239. doi: 10.3904/kjim.2016.229Park H.K., Kwak M.K., Kim H.J., Ahima R.S. Linking resistin, inflammation, and cardiometabolic diseases. The Korean Journal of Internal Medicine, 2017; 32 (2): 239. doi: 10.3904/kjim.2016.229di Pietro N., Formoso G., Pandolfi A. Physiology and pathophysiology of oxLDL uptake by vascular wall cells in atherosclerosis. Vascular Pharmacology, 2016; 84: 1–7. doi: 10.1016/j.vph.2016.05.013di Pietro N., Formoso G., Pandolfi A. Physiology and pathophysiology of oxLDL uptake by vascular wall cells in atherosclerosis. Vascular Pharmacology, 2016; 84: 1–7. doi: 10.1016/j.vph.2016.05.013Fong L.G., Fong T.A., Cooper A.D. Inhibition of lipopolysaccharide-induced interleukin-1 beta mRNA expression in mouse macrophages by oxidized low density lipoprotein. J. Lipid. Res., 1991; 32: 1899– 1910. doi: 10.1016/S0022-2275(20)41893-0Fong L.G., Fong T.A., Cooper A.D. Inhibition of lipopolysaccharide-induced interleukin-1 beta mRNA expression in mouse macrophages by oxidized low density lipoprotein. J. Lipid. Res., 1991; 32: 1899– 1910. doi: 10.1016/S0022-2275(20)41893-0Okumura T., Fujioka Y., Morimoto S., Masai M., Sakoda T., Tsujino T. Chylomicron remnants stimulate release of interleukin-1beta by THP-1 cells. J. Atheroscler. Thromb., 2006; 13: 438–450. doi: 10.5551/jat.13.38Okumura T., Fujioka Y., Morimoto S., Masai M., Sakoda T., Tsujino T. Chylomicron remnants stimulate release of interleukin-1beta by THP-1 cells. J. Atheroscler. Thromb., 2006; 13: 438–450. doi: 10.5551/jat.13.38Manica-Cattani M.F., Duarte M.M.M.F., Ribeiro E.E., de Oliveira R., da Cruz I.B.M. Effect of the interleukin-1B gene on serum oxidized low-density lipoprotein levels. Clin. Biochem., 2012; 45 (9): 641–645. doi: 10.1016/j.clinbiochem.2012.02.023Manica-Cattani M.F., Duarte M.M.M.F., Ribeiro E.E., de Oliveira R., da Cruz I.B.M. Effect of the interleukin-1B gene on serum oxidized low-density lipoprotein levels. Clin. Biochem., 2012; 45 (9): 641–645. doi: 10.1016/j.clinbiochem.2012.02.023Petersen M.C., Shulman G.I. Mechanisms of insulin action and insulin resistance. Physiol. Rev., 2018; 98 (4): 2133–2223. doi: 10.1152/physrev.00063.2017Petersen M.C., Shulman G.I. Mechanisms of insulin action and insulin resistance. Physiol. Rev., 2018; 98 (4): 2133–2223. doi: 10.1152/physrev.00063.2017Föger B. Lipid lowering therapy in type 2 diabetes. Wien. Med. Wochenschr., 2011; 161 (11-12): 289–296. doi: 10.1007/s10354-011-0908-4Föger B. Lipid lowering therapy in type 2 diabetes. Wien. Med. Wochenschr., 2011; 161 (11-12): 289–296. doi: 10.1007/s10354-011-0908-4Monnier L., Hanefeld M., Schnell O., Colette C., Owens D. Insulin and atherosclerosis: how are they related? Diabetes & Metabolism, 2013; 39 (2): 111– 117. doi: 10.1016/j.diabet.2013.02.001Monnier L., Hanefeld M., Schnell O., Colette C., Owens D. Insulin and atherosclerosis: how are they related? Diabetes & Metabolism, 2013; 39 (2): 111– 117. doi: 10.1016/j.diabet.2013.02.001Aslan I., Kucuksayan E., Aslan M. Effect of insulin analog initiation therapy on LDL/HDL subfraction profile and HDL associated enzymes in type 2 diabetic patients. Lipids in Health and Disease, 2013; 12 (1): 1–11. doi: 10.1186/1476-511X-12-54Aslan I., Kucuksayan E., Aslan M. Effect of insulin analog initiation therapy on LDL/HDL subfraction profile and HDL associated enzymes in type 2 diabetic patients. Lipids in Health and Disease, 2013; 12 (1): 1–11. doi: 10.1186/1476-511X-12-54Chaudhuri A., Dandona P. Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes. Diabetes, Obesity and Metabolism, 2011; 13 (10): 869–879. doi: 10.1111/j.14631326.2011.01423.xChaudhuri A., Dandona P. Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes. Diabetes, Obesity and Metabolism, 2011; 13 (10): 869–879. doi: 10.1111/j.14631326.2011.01423.xScherer T., Lindtner C., O’Hare J., Hackl M., Zielinski E., Freudenthaler A., Buettner C. Insulin regu- lates hepatic triglyceride secretion and lipid content via signaling in the brain. Diabetes, 2016; 65 (6): 1511–1520. doi: 10.2337/db15-1552Scherer T., Lindtner C., O’Hare J., Hackl M., Zielinski E., Freudenthaler A., Buettner C. Insulin regu- lates hepatic triglyceride secretion and lipid content via signaling in the brain. Diabetes, 2016; 65 (6): 1511–1520. doi: 10.2337/db15-1552Nolan C.J., Ruderman N.B., Kahn S.E., Pedersen O., Prentki, M. Insulin resistance as a physiological defense against metabolic stress: implications for the management of subsets of type 2 diabetes. Diabetes, 2015; 64 (3): 673–686. doi: 10.2337/db14-0694Nolan C.J., Ruderman N.B., Kahn S.E., Pedersen O., Prentki, M. Insulin resistance as a physiological defense against metabolic stress: implications for the management of subsets of type 2 diabetes. Diabetes, 2015; 64 (3): 673–686. doi: 10.2337/db14-0694Izquierdo A.G., Crujeiras A.B., Casanueva F.F., Carreira M.C. Leptin, obesity, and leptin resistance: where are we 25 years later. Nutrients, 2019; 11 (11): 2704. doi: 10.3390/nu11112704Izquierdo A.G., Crujeiras A.B., Casanueva F.F., Carreira M.C. Leptin, obesity, and leptin resistance: where are we 25 years later. Nutrients, 2019; 11 (11): 2704. doi: 10.3390/nu11112704Lloyd D.J., McCormick J., Helmering J., Kim K.W., Wang M., Fordstrom P., Vйniant M. M. Generation and characterization of two novel mouse models exhibiting the phenotypes of the metabolic syndrome: Apob48–/–Lepob/ob mice devoid of ApoE or Ldlr. Am. J. Physiol. Endocrinol. Metab., 2008; 294 (3): 496–505. doi: 10.1152/ajpendo.00509.2007Lloyd D.J., McCormick J., Helmering J., Kim K.W., Wang M., Fordstrom P., Vйniant M. M. Generation and characterization of two novel mouse models exhibiting the phenotypes of the metabolic syndrome: Apob48–/–Lepob/ob mice devoid of ApoE or Ldlr. Am. J. Physiol. Endocrinol. Metab., 2008; 294 (3): 496–505. doi: 10.1152/ajpendo.00509.2007Bodary P.F., Gu S., Shen Y., Hasty A.H., Buckler J.M., Eitzman D.T. Recombinant leptin promotes atherosclerosis and thrombosis in apolipoprotein E-deficient mice. Arterioscler., Thrombosis, and Vascular Biol., 2005; 25 (8): 119–122. doi: 10.1161/01.ATV.0000173306.47722.ecBodary P.F., Gu S., Shen Y., Hasty A.H., Buckler J.M., Eitzman D.T. Recombinant leptin promotes atherosclerosis and thrombosis in apolipoprotein E-deficient mice. Arterioscler., Thrombosis, and Vascular Biol., 2005; 25 (8): 119–122. doi: 10.1161/01.ATV.0000173306.47722.ecMetlakunta A., Huang W., Stefanovic-Racic M., Dedousis N., Sipula I., O’Doherty R.M. Kupffer cells facilitate the acute effects of leptin on hepatic lipid metabolism. Am. J. Physiol. Endocrinol. Metab., 2017; 312 (1): 11–18. doi: 10.1152/ajpendo.00250.2016Metlakunta A., Huang W., Stefanovic-Racic M., Dedousis N., Sipula I., O’Doherty R.M. Kupffer cells facilitate the acute effects of leptin on hepatic lipid metabolism. Am. J. Physiol. Endocrinol. Metab., 2017; 312 (1): 11–18. doi: 10.1152/ajpendo.00250.2016Huang W., Metlakunta A., Dedousis N., Ortmeyer H.K., Stefanovic-Racic M., O’Doherty R.M. Leptin augments the acute suppressive effects of insulin on hepatic very low-density lipoprotein production in rats. Endocrinology, 2009; 150 (5): 2169–2174. doi: 10.1210/en.2008-1271Huang W., Metlakunta A., Dedousis N., Ortmeyer H.K., Stefanovic-Racic M., O’Doherty R.M. Leptin augments the acute suppressive effects of insulin on hepatic very low-density lipoprotein production in rats. Endocrinology, 2009; 150 (5): 2169–2174. doi: 10.1210/en.2008-1271Prieur X., Le May C., Magré J., Cariou B. Congenital lipodystrophies and dyslipidemias. Curr. Atheroscler. Rep., 2014; 16 (9); 1–11. doi: 10.1007/s11883-014-0437-xPrieur X., Le May C., Magré J., Cariou B. Congenital lipodystrophies and dyslipidemias. Curr. Atheroscler. Rep., 2014; 16 (9); 1–11. doi: 10.1007/s11883-014-0437-xChong A.Y., Lupsa B.C., Cochran E.K., Gorden P. Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia, 2010; 53 (1): 27–35. doi: 10.1007/s00125-009-1502-9.Chong A.Y., Lupsa B.C., Cochran E.K., Gorden P. Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia, 2010; 53 (1): 27–35. doi: 10.1007/s00125-009-1502-9.Salas-Salvadó J., Díaz-López A., Ruiz-Canela M., Basora J., Fitó M., Corella D., Martínez-González M.Á. Effect of a lifestyle intervention program with energyrestricted Mediterranean diet and exercise on weight loss and cardiovascular risk factors: one-year results of the PREDIMED-Plus trial. Diabetes Care, 2019; 42 (5): 777–788. doi: 10.2337/dc18-0836Salas-Salvadó J., Díaz-López A., Ruiz-Canela M., Basora J., Fitó M., Corella D., Martínez-González M.Á. Effect of a lifestyle intervention program with energyrestricted Mediterranean diet and exercise on weight loss and cardiovascular risk factors: one-year results of the PREDIMED-Plus trial. Diabetes Care, 2019; 42 (5): 777–788. doi: 10.2337/dc18-0836Sartipy P., Loskutoff D.J. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc. Nat. Acad. Sci., 2003; 100 (12): 7265–7270. doi: 10.1073/pnas.1133870100Sartipy P., Loskutoff D.J. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc. Nat. Acad. Sci., 2003; 100 (12): 7265–7270. doi: 10.1073/pnas.1133870100Sun R.L., Huang C.X., Bao J.L., Jiang J.Y., Zhang B., Zhou S.X., Zhang Y.L. CC-chemokine ligand 2 (CCL2) suppresses high density lipoprotein (HDL) internalization and cholesterol efflux via CCchemokine receptor 2 (CCR2) induction and p42/44 mitogen-activated protein kinase (MAPK) activation in human endothelial cells. J. Biol. Chem., 2016; 291 (37): 19532–19544. doi: 10.1074/jbc.M116.714279Sun R.L., Huang C.X., Bao J.L., Jiang J.Y., Zhang B., Zhou S.X., Zhang Y.L. CC-chemokine ligand 2 (CCL2) suppresses high density lipoprotein (HDL) internalization and cholesterol efflux via CCchemokine receptor 2 (CCR2) induction and p42/44 mitogen-activated protein kinase (MAPK) activation in human endothelial cells. J. Biol. Chem., 2016; 291 (37): 19532–19544. doi: 10.1074/jbc.M116.714279Лазаренко В.А., Бобровская Е.А., Путинцева Е.В., Бондарев Г.А. Окисленные липопротеины низкой плотности до и после реконструктивных вмешательств на магистральных артериях нижних конечностей. Вестник Национального медико-хирургического центра им. Н.И. Пирогова, 2015; 10 (1): 14–17. www.elibrary.ru/item.asp?id=26713873Lazarenko V.A., Bobrovskaya E.A., Putintseva E.V., Bondarev G.A. Oxidized low-density lipoproteins before and after reconstructive interventions on the main arteries of the lower extremities. Vestnik Natsionalnogo mediko-khirurgicheskogo tsentra im. N.I. Pirogova, 2015; 10 (1): 14–17. (In Russ.)Autry A.E., Monteggia L.M. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol. Rev., 2012; 64 (2): 238–258. doi: 10.1124/pr.111.005108Autry A.E., Monteggia L.M. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol. Rev., 2012; 64 (2): 238–258. doi: 10.1124/pr.111.005108Minnone G., de Benedetti F., Bracci-Laudiero L. NGF and its receptors in the regulation of inflammatory response. Int. J. Mol. Sci., 2017; 18 (5): 1028. doi: 10.3390/ijms18051028Minnone G., de Benedetti F., Bracci-Laudiero L. NGF and its receptors in the regulation of inflammatory response. Int. J. Mol. Sci., 2017; 18 (5): 1028. doi: 10.3390/ijms18051028Mantyh P.W., Koltzenburg M., Mendell L.M., Tive L., Shelton D.L., Warner D.S. Antagonism of nerve growth factor-TrkA signaling and the relief of pain. The J. Am. Soc. Anesthesiol., 2011; 115 (1): 189–204. doi: 10.1097/ALN.0b013e31821b1ac5Mantyh P.W., Koltzenburg M., Mendell L.M., Tive L., Shelton D.L., Warner D.S. Antagonism of nerve growth factor-TrkA signaling and the relief of pain. The J. Am. Soc. Anesthesiol., 2011; 115 (1): 189–204. doi: 10.1097/ALN.0b013e31821b1ac5Do H.T., Bruelle C., Pham D.D., Jauhiainen M., Eriksson O., Korhonen L.T., Lindholm D. Nerve growth factor (NGF) and pro-NGF increase lowdensity lipoprotein (LDL) receptors in neuronal cells partly by different mechanisms: role of LDL in neurite outgrowth. J. Neurochem., 2016; 136 (2): 306–315. doi: 10.1111/jnc.13397Do H.T., Bruelle C., Pham D.D., Jauhiainen M., Eriksson O., Korhonen L.T., Lindholm D. Nerve growth factor (NGF) and pro-NGF increase lowdensity lipoprotein (LDL) receptors in neuronal cells partly by different mechanisms: role of LDL in neurite outgrowth. J. Neurochem., 2016; 136 (2): 306–315. doi: 10.1111/jnc.13397Teplan V., Senolt L., Hulejova H., Stollova M., Gurlich R. Early changes in serum visfatin after abdominal surgery: a new pro-inflammatory marker in diagnosis? Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia. 2014; 159 (3): 489–496. doi: 10.5507/bp.2014.012Teplan V., Senolt L., Hulejova H., Stollova M., Gurlich R. Early changes in serum visfatin after abdominal surgery: a new pro-inflammatory marker in diagnosis? Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia. 2014; 159 (3): 489–496. doi: 10.5507/bp.2014.012Кузнецова Л.А., Шпаков А.О. Адипокины и их возможная роль в ожирении и сахарном диабете 2-го типа. Саратовский научномедицинский журнал, 2018; 14 (2): 201–206. www.elibrary.ru/item.asp?id=3574179Kuznetsova L.A., Shpakov A.O. Adipokines and their possible role in obesity and type 2 diabetes mellitus. Saratovskiy nauchno-meditsinskiy zhurnal, 2018; 14 (2): 201–206 (In Russ.)Naz R., Tauqeer S., Bibi Y., Ayub M. Level of visfatin in obese and diabetic Balb/c mice. Pak. J. Physiol., 2017; 13 (3): 36–38. www.pps.org.pk/PJP/13-3/Raeesa.pdNaz R., Tauqeer S., Bibi Y., Ayub M. Level of visfatin in obese and diabetic Balb/c mice. Pak. J. Physiol., 2017; 13 (3): 36–38. www.pps.org.pk/PJP/13-3/Raeesa.pdShafeeq N.K. Visfatin PON-1 Levels in Iraqi Hyperthyroidism Patient’s with Dyslipidemia. Indian J. Clin. Biochem., 2019; 34 (1): 101–107. doi: 10.1007/s12291-017-0717-7Shafeeq N.K. Visfatin PON-1 Levels in Iraqi Hyperthyroidism Patient’s with Dyslipidemia. Indian J. Clin. Biochem., 2019; 34 (1): 101–107. doi: 10.1007/s12291-017-0717-7Бардымова Т.П., Березина М.В., Батунова Е.В., Мирошниченко И.А. Метаболические особенности пациентов с ожирением. Медицинский совет, 2017; 20: 157–159. doi: 10.21518/2079-701X-2017-20-157-159Bardymova T.P., Berezina M.V., Batunova E.V., Miroshnichenko I.A. Metabolic features of obese patients. Meditsinskii sovet, 2017; 20: 157–159 (In Russ.)Pan X., Kaminga A.C., Wen S.W., Acheampong K., Liu A. Omentin-1 in diabetes mellitus: A systematic review and meta-analysis. PLoS One, 2019; 14 (12): e0226292. doi: 10.1093/cvr/cvw016.Pan X., Kaminga A.C., Wen S.W., Acheampong K., Liu A. Omentin-1 in diabetes mellitus: A systematic review and meta-analysis. PLoS One, 2019; 14 (12): e0226292. doi: 10.1093/cvr/cvw016.Lesná J., Tichá A., Hyšpler R., Musil F., Bláha V., Sobotka L., Šmahelová A. Omentin-1 plasma levels and cholesterol metabolism in obese patients with diabetes mellitus type 1: impact of weight reduction. Nutrition & Diabetes, 2015; 5 (11): 183–183. doi: 10.1038/nutd.2015.33Lesná J., Tichá A., Hyšpler R., Musil F., Bláha V., Sobotka L., Šmahelová A. Omentin-1 plasma levels and cholesterol metabolism in obese patients with diabetes mellitus type 1: impact of weight reduction. Nutrition & Diabetes, 2015; 5 (11): 183–183. doi: 10.1038/nutd.2015.33Moreno-Navarrete J.M., Catalán V., Ortega F., Gómez-Ambrosi J., Ricart W., Frühbeck G., Fernández-Real J.M. Circulating omentin concentration increases after weight loss. Nutrition & Metabolism, 2010; 7 (1): 1–6. doi: 10.1186/1743-7075-7-27Moreno-Navarrete J.M., Catalán V., Ortega F., Gómez-Ambrosi J., Ricart W., Frühbeck G., Fernández-Real J.M. Circulating omentin concentration increases after weight loss. Nutrition & Metabolism, 2010; 7 (1): 1–6. doi: 10.1186/1743-7075-7-27Watanabe K., Watanabe R., Konii H., Shirai R., Sato K., Matsuyama T.A., Ishibashi-Ueda H., Koba S., Kobayashi Y., Hirano T., Watanabe T. Counteractive effects of omentin-1 against atherogenesis. Cardiovasc. Res., 2016; 110 (1): 118–128. doi: 10.1093/cvr/cvw016Watanabe K., Watanabe R., Konii H., Shirai R., Sato K., Matsuyama T.A., Ishibashi-Ueda H., Koba S., Kobayashi Y., Hirano T., Watanabe T. Counteractive effects of omentin-1 against atherogenesis. Cardiovasc. Res., 2016; 110 (1): 118–128. doi: 10.1093/cvr/cvw016

The authors declare that there are no conflicts of interest present.